FDA Reconsidering Medstone STS Lithotripter PMA For Gallstone Treatment
This article was originally published in The Gray Sheet
Medstone International is developing a protocol for a post-approval clinical study of the firm's STS lithotripter for gallstone treatment as FDA begins to revisit its August 1998 decision to reject the firm's premarket approval application.
You may also be interested in...
Medstone International should conduct post-approval studies of its STS lithotripter in combination with Novartis' Actigall (ursodiol) anti-gallstone drug to fragment biliary stones, FDA's Gastroenterology and Urology Devices Panel recommended April 30.
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.